Should I buy Canopy Growth stock in 2025?

Why trust HelloSafe?

At HelloSafe, our expert has been monitoring the performance of Canopy Growth for over three years. Every month, hundreds of thousands of users in Canada rely on us to interpret market trends and highlight the best investment opportunities. Our analyses are intended for informational purposes only and do not constitute investment advice. Consistent with our code of ethics, we have never been, and will never be, compensated by Canopy Growth.

What is Canopy Growth?

How much is Canopy Growth stock?

The price of Canopy Growth stock is rising this week. As of April 30, 2025, WEED shares are trading at $1.90 CAD, reflecting a 1.04% drop over 24 hours but delivering a 10% gain over the past week. The company’s market capitalization stands at approximately $345 million CAD, with a 3-month average trading volume of 8.28 million shares. There is currently no positive P/E ratio, and the stock does not offer a dividend yield. The beta indicates high volatility, recently measured at 1.93. With its heightened trading activity and recent momentum, Canopy Growth remains a dynamic but volatile choice for Canadian investors seeking exposure to the cannabis sector.

Our full analysis on Canopy Growth stock

After an in-depth review of Canopy Growth Corporation’s most recent financial results, and a rigorous assessment of its stock performance over the last three years, our analysis synthesizes financial, technical, and market data using proprietary analytical algorithms. By interrogating a multitude of indicators and benchmarking against key competitors, we have built a holistic view of Canopy Growth’s trajectory, resilience, and potential. So, why might Canopy Growth stock once again become a strategic entry point into the cannabis and emerging healthcare sectors in 2025?

Recent Performance and Market Context

Over the past three years, Canopy Growth (NASDAQ: CGC, TSX: WEED) has navigated a fiercely competitive landscape, marked by evolving regulations and multi-year sector re-rating. Despite a pronounced stock price correction—CGC shares now trade at $1.38 USD on the NASDAQ and $1.90 CAD on the TSX, down over 90% year-on-year—the company has demonstrated signs of stabilization and renewed investor attention. Notably, in Q3 FY2025, Canopy Growth improved its operating loss by 61% and delivered adjusted EBITDA performance materially better than last year.

Contributing to the stock’s evolving narrative are several favorable events:

• Debt reduction: Total liabilities were trimmed by over CA$100 million in the past quarter alone, underscoring a disciplined capital structure approach.
• International growth: With revenues in Poland and Germany surging and the Storz & Bickel vaporizer segment expanding almost 20% year-over-year, Canopy is unlocking new profit centers.
• Domestic resilience: Despite overall Canadian adult-use cannabis market challenges, medical cannabis revenue climbed 16% year-over-year, while adult-use revenue bounced 15% sequentially, hinting at a baseline resurgence.

The macro backdrop is also turning increasingly supportive. Canadian cannabis legal frameworks remain robust, and recent regulatory relaxations in Europe—particularly the German cannabis market’s liberalization—open meaningful near-term addressable markets. Furthermore, potential U.S. federal reform stands as a latent, outsized catalyst for all multi-national operators.

Technical Analysis

Examining CGC’s technical landscape reveals constructive undertones and the potential for a structural bullish inflection:

• Relative Strength Index (RSI 14) at 59.99 suggests balanced momentum—neither overbought nor oversold—highlighting potential for directional moves without exhaustion.
• MACD (12,26) reads slightly negative at 0.05; however, the trend is flattening, indicating a poised state that could quickly pivot positive on incremental buying.
• Moving averages present a nuanced picture:
• All key short-term measures (5, 10, 20, 50 days) currently signal “Buy,” reflecting renewed upward momentum.
• The 50-day moving average ($1.19) positions below price, operating as immediate support and validating short-term upside structure.
• While the 100- and 200-day averages remain in “Sell,” signalling residual long-term caution, the proximity of resistance ($1.41-$1.56) means a confirmed break could trigger a more forceful bullish shift.

Key support is well-anchored at $1.18-$1.26, with upward targets at $1.41 and $1.56 representing tactical zones for medium-term trading strategies. The technical setup thus underpins an argument for favorable risk/reward asymmetry at current price levels.

Fundamental Analysis

Fundamentally, Canopy Growth is charting a meaningful path through restructuring and healthcare segment expansion:

• Revenue dynamics: Excluding divestitures, revenue growth is running at 8% on a yearly basis—contrasting sector-wide contraction and pointing to share recapture.
• Profitability trajectory: The operating loss contraction and a 61% improvement in adjusted EBITDA underscore operational leverage—a clear sign that cost management programs are taking effect.
• Valuation: The company’s market capitalization of $251 million USD belies its global footprint, diverse product offering, and latent U.S. option value. While Canopy does not currently trade at a positive P/E ratio, its Price-to-Sales (P/S) stands at a multi-year low, suggesting the market is discounting overly conservative expectations.
• Innovative capacity: Strategic launches, such as the Claybourne infused pre-roll line achieving top regional market share in a matter of weeks, reinforce Canopy’s brand strength and adaptable product development engine.
• International diversification: Operations in Germany, Poland, and Australia provide structural market diversification that insulates Canopy from isolated domestic shocks—an advantage magnified by its leading position in high-growth European markets.

In addition, Storz & Bickel’s robust trajectory highlights Canopy’s ability to innovate in wellness-oriented, premium vaporization—an area with superior gross margin potential.

Volume and Liquidity

CGC’s liquidity profile is highly attractive for both retail and institutional participants:

• Elevated volume: The average 65-day trading volume exceeds 8 million shares, and recent trading sessions have recorded 14.86 million shares, or 179% of average activity. This uptick in volume is typically interpreted as a sign of market validation and deepening investor engagement.
• Favorable float structure: The stock’s mid-tier market capitalization and actively traded float support dynamic price discovery, while controlling for excessive dilution risk. This liquidity level enables sophisticated entry and exit strategies with minimized slippage, even amidst sector volatility.

Sustained volume, coupled with a stabilizing price base, reflects a decisive reduction in forced or panic selling and hints at institutional bottom-fishing and speculative accumulation.

Catalysts and Positive Outlook

Several actionable catalysts position Canopy Growth for an upwards business and share price trajectory:

• Medical cannabis momentum: As payors increasingly recognize medical cannabis value, Canopy’s 16% segment growth—at higher average margins—fortifies its financial base and reinforces a premium brand halo.
• Regulatory catalysts: The German parliament’s recent legalization of adult-use cannabis creates an immediate multi-billion-euro addressable market, with Canopy among few North American operators poised for scale.
• U.S. market optionality: The company’s strategic structure through Canopy USA, LLC, and recent moves to consolidate Acreage, Wana, and Jetty, provide pure-play upside in the event of U.S. federal cannabis reform—a prospect that could rapidly transform current valuation paradigms.
• Product innovation: The rapid rise of Claybourne products and the market dominance of Storz & Bickel support a narrative of consumer-focused innovation that feeds pricing power and margin expansion.
• Operational discipline: Ongoing debt reduction, targeted cost-cutting, and a path toward free cash flow neutrality should incrementally derisk the investment case while supporting a rerating.
• ESG leadership: Canopy’s emphasis on renewable energy sources and responsible cultivation practices may further differentiate the company, aligning with a rapidly growing cohort of sustainability-focused investors.

Given this multi-dimensional catalyst pipeline, the groundwork appears set for operational and financial inflection—reinforcing investor confidence in Canopy Growth’s turnaround potential.

Investment Strategies

A variety of tactical and strategic positions emerge for investors considering Canopy Growth in 2025:

• Short-term entry: Technical momentum above $1.19 support, combined with high trading volumes and positive short-term signals, favor speculative or event-driven trades, especially ahead of U.S. regulatory updates or quarterly results. A break above $1.41 could add momentum-driven upside.
• Medium-term positioning: Core drivers such as international expansion (notably in Germany and Poland), successful product launches, and free cash flow improvement argue for accumulating shares at current levels or on any minor technical pullbacks near $1.18-$1.26.
• Long-term thesis: For investors with higher risk tolerance, Canopy Growth may represent an asymmetric, option-like exposure to global cannabis legalization, medical market growth, and emerging mainstream acceptance. The company’s brand portfolio and early moves in the U.S. set the stage for a re-rating should regulatory tailwinds materialize.

Importantly, accumulating positions at this apparent technical low—before potential shift events—positions investors to benefit from both cyclical rebounds and structural evolutions in the cannabis industry.

Is it the Right Time to Buy Canopy Growth?

In aggregate, Canopy Growth’s evolving financial, technical, and operational picture signals a company at an inflection point, with multiple levers for upside:

• Operational turnaround: Dramatic improvement in adjusted EBITDA and successful cost discipline underpin renewed confidence in management execution.
• Revenue momentum: Segmental growth in medical cannabis, international, and premium vaporizer sales validate the company’s multi-faceted strategy.
• Catalyst-rich outlook: Immediate avenues for expansion in Germany and potential for transformative U.S. entry drive meaningful latent value.
• Liquidity and entry point: Heightened trading volume and technical basing provide an ideal environment for new entrants—mitigating risk of “catching a falling knife” and amplifying the risk/reward skew to the upside.

While sector volatility remains high and some uncertainties persist, the convergence of technical stabilization, improving fundamentals, aggressive cost discipline, and significant near- and medium-term catalysts means that Canopy Growth seems to represent an excellent opportunity for investors seeking exposure to the next chapter of the cannabis industry. The fundamentals increasingly justify renewed investor interest, and the stock may well be entering a new bullish phase driven by both operational execution and external tailwinds—inviting a serious, well-considered look from strategic investors.

For those seeking early entry into a potential turnaround story in a sector poised for global normalization, Canopy Growth offers a compelling risk-adjusted profile—anchored in operational recovery, innovation, and a catalyst-rich environment—making it especially worthy of attention as we look toward 2025.

How to buy Canopy Growth stock in Canada?

Buying Canopy Growth stock online in Canada is both simple and secure when using a regulated brokerage. Investors can choose to buy shares directly (spot buying) or trade the stock via Contracts for Difference (CFDs) — each offering unique advantages. Spot buying makes you a shareholder with direct ownership, while CFDs let you trade price movements with leverage. Both methods prioritize safety with Canadian investor protections in place. To help you find the platform that best fits your needs and budget, a detailed broker comparison is provided further down the page.

Spot buying

A cash (spot) purchase means you’re buying actual Canopy Growth shares via your investment account, typically on the TSX (symbol: WEED). This gives you direct ownership: you can benefit from price rises and, if any are issued, dividends or voting rights. Canadian brokerages usually charge a fixed commission per trade, often ranging from $5 to $10.

Important Example

Example: With Canopy Growth trading at $1.90 CAD per share, a $1,000 investment (minus a typical $5 brokerage fee) lets you buy around 523 shares:
- $1,000 - $5 = $995 available to invest
- $995 ÷ $1.90 ≈ 523 shares
✔️ Gain scenario: If the share price increases by 10% (to $2.09 CAD), your position’s value grows to about $1,100.
Result: +$100 gross gain, or +10% on your investment.

Trading via CFD

A CFD (Contract for Difference) lets you speculate on Canopy Growth’s price movement without owning the underlying shares. Popular with active traders, CFDs offer leverage, so you can access larger positions with a smaller capital outlay. With most brokers, you pay the spread (the small difference between buy/sell prices), and if you hold overnight, a daily financing fee applies.

Important Example

Example: With a $1,000 deposit and 5× leverage, you control $5,000 worth of Canopy Growth shares.
✔️ Gain scenario: If the stock rises by 8%, your gain is 8% × 5 = 40%. That’s a $400 profit on your $1,000 margin, excluding fees.
Keep in mind: CFD trading amplifies both gains and potential losses and doesn’t confer shareholder rights.

Final advice

Before investing in Canopy Growth, it’s essential to compare brokerage fees, commissions, and trading conditions. Each broker’s pricing and platform features can impact your returns, so don’t skip this step — our comparator below will help. Ultimately, the right method depends on your goals: spot buying suits longer-term investors aiming for ownership, while CFD trading is tailored for short-term, active market participants seeking flexibility and leverage.

Platforms

Minimum Deposit

Discover

#1

Tier 1 regulation, including ASIC and FSA

#1

Star Trader

4.9

Minimum Deposit

$50

Discover

with our partner Star Trader

#2

Broker specializing in Forex and CFDs

#2

IFC Markets

4.8

Minimum Deposit

$1

Discover

with our partner IFC Markets

#3

Broker regulated since 2006

#3

Avatrade

4.8

Minimum Deposit

$100

Discover

with our partner Avatrade

Our 7 tips for buying Canopy Growth stock

The latest news about Canopy Growth

Canopy Growth delivered notable progress in medical cannabis growth and profitability in Canada over the past quarter. In Q3 FY2025, the company reported that Canadian medical cannabis revenues increased by 16% year-over-year, representing a high-margin segment that remains a pillar of Canopy’s domestic operations. This medical momentum—against a backdrop of overall industry commoditization—helped the company narrow its operating loss by 61% and improve adjusted EBITDA loss by the same margin compared to last year. Cost improvement initiatives and tighter financial discipline have resulted in a smaller free cash outflow, signaling improved operational efficiency positioned for the Canadian market.

New product launches have rapidly garnered market share in Canada’s largest provinces, supporting brand strength. The company’s Claybourne infused pre-rolls made a remarkable entrance, achieving the number three market share position in British Columbia and Ontario just six weeks after launch. This swift success underscores Canopy Growth’s ability to respond to evolving consumer preferences within the recreational market, as well as to innovate within crowded product categories. Such traction in Canadian provinces with sizeable retail footprints demonstrates the capability of Canopy’s portfolio to resonate with local consumers and to potentially capture incremental market share despite ongoing price competition.

Canopy Growth’s recent financial update shows substantial debt reduction and improved cash flow, strengthening its balance sheet. Over the past quarter, the company reduced its total debt from $554 million CAD to $442 million CAD and enhanced its free cash flow position by 17% year-over-year. These improvements are crucial within the context of the highly competitive Canadian cannabis market, where continued access to capital and financial resilience are key strategic assets. The decreased financial leverage provides greater flexibility for reinvestment in priority growth segments and could contribute positively to sentiment among Canadian institutional investors.

Strong international revenue growth, particularly in Germany and Poland, signals diversification beyond the domestic Canadian market. International segment sales rose by 14% year-over-year in Q3 FY2025, outpacing most Canadian peers. This expansion is especially significant for Canadian stakeholders, as ongoing reforms and liberalization in European medical cannabis offer Canopy potential new channels and revenue streams. Positive developments in Germany, poised to become one of the largest regulated cannabis markets outside North America, represent a strategic advantage for Canopy given its early presence.

Recent technical and trading signals highlight increased investor activity and modest price momentum for Canopy’s Canadian listing. Despite a broader negative trend in the sector, Canopy’s TSX-listed shares have seen a significant pickup in trading volumes—recent sessions surged to 179% of average daily volume—which may reflect rising local interest and volatility-driven opportunities. The short-term moving averages now signal “Buy,” suggesting possible near-term stabilization. For Canada-based analysts, such market signals are constructive, especially when considered alongside improving fundamentals and operational discipline.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.